Literature DB >> 12572838

Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy.

C Kampmann1, C M Wiethoff, C Martin, A Wenzel, R Kampmann, C Whybra, E Miebach, M Beck.   

Abstract

AIMS: Fabry disease results from deficient activity of the lysosomal enzyme alpha-galactosidase A. Progressive accumulation of the major substrates leads, in both men and women, to progressive hypertrophic cardiomyopathy. We aimed to evaluate the utility of different electrocardiographic (ECG) parameters for assessing the degree and severity of hypertrophic cardiomyopathy in patients with Fabry disease.
METHODS: A total of 166 ECGs of 94 hemi- and heterozygous patients with Fabry disease were analysed and compared with echocardiographic-estimated left ventricular mass (LVM).
RESULTS: There was a significant (p < 0.0001) correlation between QRS duration (R2 = 0.59), 12-lead amplitude/duration product (R2 = 0.61), Sokolow-Lyon voltage/duration product (R2 = 0.52) and LVM. Analysis of receiver operating characteristics revealed that the 12-lead amplitude/duration product had the highest sensitivity-specificity relationship (p < 0.01 compared with the Cornell index).
CONCLUSION: In general, ECG signs of left ventricular hypertrophy correlated well with LVM as revealed by echocardiography. Of the parameters studied, the 12-lead amplitude/duration product was the most successful at describing the severity of cardiac involvement in Fabry disease. These data suggest that ECG parameters have potential for use as a simple and cost-effective means of screening for hypertrophic cardiomyopathy in patients with Fabry disease.

Entities:  

Mesh:

Year:  2002        PMID: 12572838     DOI: 10.1111/j.1651-2227.2002.tb03105.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  7 in total

Review 1.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

2.  Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease.

Authors:  Markus Niemann; Tanja Hartmann; Mehdi Namdar; Frank Breunig; Meinrad Beer; Wolfram Machann; Sebastian Herrmann; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

3.  Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement.

Authors:  Raphael Schiffmann; Amy Rapkiewicz; Mones Abu-Asab; Markus Ries; Hasan Askari; Maria Tsokos; Martha Quezado
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

Review 4.  2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

Authors:  Chung-Lieh Hung; Yen-Wen Wu; Chih-Chan Lin; Chih-Hung Lai; Jimmy Jyh-Ming Juang; Ting-Hsing Chao; Ling Kuo; Kuo-Tzu Sung; Chao-Yung Wang; Chun-Li Wang; Chun-Yuan Chu; Wen-Chung Yu; Charles Jia-Yin Hou
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

5.  Electrical Changes in Resting, Exercise, and Holter Electrocardiography in Fabry Cardiomyopathy.

Authors:  Johannes Krämer; Peter Nordbeck; Stefan Störk; Christian Ritter; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  JIMD Rep       Date:  2015-10-27

6.  Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.

Authors:  Christoph Kampmann; Amandine Perrin; Michael Beck
Journal:  Orphanet J Rare Dis       Date:  2015-09-29       Impact factor: 4.123

7.  Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease.

Authors:  Matthew Zada; Queenie Lo; Siddharth J Trivedi; Mehmet Harapoz; Anita C Boyd; Kerry Devine; Norman Sadick; Michel C Tchan; Liza Thomas
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.